XORTX Therapeutics Inc. (XRTX), a late-stage clinical pharmaceutical company, Thursday announced the appointment of biotech/pharma industry veteran Michael Bumby as Chief Financial Officer.
Bumby, who is replacing CFO James Fairbairn, is currently a director and audit committee chair of MediPharm Labs following their acquisition of VIVO Cannabis Inc. He was the CFO of VIVO for six years.
Previously, he had a 14-year career at drug major Eli Lilly.
Chairman Anthony Giovinazzo said, "His dual science-finance background and extensive business and drug development experience will help XORTX meet its near and longer-term objectives."
XRTX closed Wednesday's regular trading 4.27% higher at $1.12 on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.